0001192482-18-000010.txt : 20180104 0001192482-18-000010.hdr.sgml : 20180104 20180104194512 ACCESSION NUMBER: 0001192482-18-000010 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180102 FILED AS OF DATE: 20180104 DATE AS OF CHANGE: 20180104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCP Vitalife Partners (Israel) II, L.P. CENTRAL INDEX KEY: 0001602484 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36329 FILM NUMBER: 18511773 BUSINESS ADDRESS: STREET 1: 32B HABARZEL STREET STREET 2: RAMAT HACHAYAL CITY: TEL AVIV STATE: L3 ZIP: 69710 BUSINESS PHONE: 610-995-2900 MAIL ADDRESS: STREET 1: SUITE 190 STREET 2: 7 GREAT VALLEY PARKWAY CITY: MALVERN STATE: PA ZIP: 19355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Recro Pharma, Inc. CENTRAL INDEX KEY: 0001588972 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261523233 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 490 LAPP ROAD CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: (484) 395-2400 MAIL ADDRESS: STREET 1: 490 LAPP ROAD CITY: MALVERN STATE: PA ZIP: 19355 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2018-01-02 0001588972 Recro Pharma, Inc. REPH 0001602484 SCP Vitalife Partners (Israel) II, L.P. SUITE 190 7 GREAT VALLEY PARKWAY MALVERN, PA 19355 0 0 1 0 Common Stock 2018-01-02 4 S 0 6329 9.037 D 734269 D Common Stock 2018-01-03 4 S 0 6635 8.733 D 727634 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.7500 to $9.1800, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.60 to $8.95, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4. /s/ Ryan Lake, Attorney-in-fact 2018-01-04